Exosomes in Facial Harmonization: Evidence and Risks

"Exosomes" show up in ads, talks and supplier messages as the next big thing in skin regeneration. The scientific interest is real: extracellular vesicles take part in communication between cells and have become a research subject in several areas of medicine. The problem is the gap between promising research and a standardized, safe and approved product for aesthetic use in the practice.

This guide is a review. It explains what exosomes are, what the evidence allows us to say, what the regulatory and health risks are, and how a clinic can decide prudently. It does not include a protocol, concentration or injection technique, and it neither recommends nor discourages any specific product. The decisions belong to the licensed professional, according to the rules of their professional board and Brazilian health legislation.

What are exosomes?

Exosomes are a type of extracellular vesicle: tiny particles wrapped in a lipid membrane, released by almost every cell. They carry proteins, lipids and fragments of genetic material, and are believed to take part in communication between cells, modulating inflammation, tissue repair and other responses. In skin research, the hypothesis is that vesicles derived from certain cells could influence fibroblasts and the production of collagen.

In commercial practice, the term "exosome" is used broadly and not always precisely. Products can contain vesicles of varying sizes, at unknown concentrations, mixed with other substances. This is one of the central problems: without standardization of the definition, dose and purity, two vials with the same word on the label can be very different things.

Where do the products come from?

The origin of the material defines a good part of the risk. The most mentioned sources are:

In every case, the safety question is: what exactly is in the vial, where did it come from, how was it purified and how was it tested? Without a documented answer, the professional has no way to guarantee sterility, absence of contaminants or the safety of the material.

What does the evidence allow us to state?

Research exists: there are laboratory studies, animal model studies and some human clinical studies, generally small, short and with products and routes of use that differ from one another. The honest reading is as follows.

• There is biological plausibility: in models, vesicles can influence skin cells.
• There are few clinical trials with good design for facial aesthetic use.
• Products are not standardized: what worked in one study does not transfer to another vial.
• Outcomes tend to be subjective (appearance, satisfaction), with unblinded assessment.
• Follow-up is short, with no solid late-safety data.

In terms of levels of evidence in facial harmonization, this is a low-evidence topic for aesthetic clinical use, with research potential. To read the papers that reach you with a critical eye, see how to read a clinical trial on injectables and publication bias in aesthetics.

What are the regulatory risks?

This is the point that matters most to the professional. Using a biological or cell-derived product for aesthetic purposes, especially by injection or combined with micro-puncture, depends on ANVISA (Brazil's health regulator) approval for that purpose and route. The regulatory situation is dynamic and varies by product, so the rule is to check each product's registration at the official source, and not to trust the supplier's word or promotional material. Consult ANVISA to verify the status of the product.

Some warning signs:

• a product with no registration number, or registered for another purpose or route;
• a supplier that does not provide documentation on origin, quality control and sterility;
• promises of results, "regeneration" or a stem cell effect;
• informal importation or sale through unregulated channels;
• a vague label on composition, concentration and expiry.

A professional who uses a product without the necessary approval can be held accountable in the health, ethical and civil spheres, and the patient is exposed to risks no one anticipated. This also applies to advertising: promoting exosomes with promises runs into the limits of what you may advertise: CFO and CONAR (in Brazil, the dental board and the advertising self-regulation body).

What about clinical safety?

The potential risks under discussion include infection (from contamination of the product or the technique), inflammatory reaction, hypersensitivity reaction, granuloma and events related to the route of application. Without standardization, there is no way to estimate the frequency of each with confidence. When the product is applied by microneedling or another technique that creates microchannels in the skin, the material comes into contact with the dermis, and the requirement for sterility and registration is even higher. See the context in microneedling with biostimulator or hyaluronic acid and in traceability of injectables.

If a complication occurs, the lack of product documentation makes diagnosis and management harder: it is not known what was applied, and hyaluronidase does not solve it, because it is not hyaluronic acid. In case of infection, remember the link to biofilm.

How do you decide prudently?

A responsible decision goes through objective questions, in the right order.

If any answer is "no," the safest course is not to use it. No commercial urgency makes up for the risk. When the subject comes from a talk or a sales rep, treat it as information to be verified, not as guidance.

How do you talk to the patient?

The patient who asks about exosomes has usually heard a promise of "regeneration." The honest answer separates the research from the available product, explains that clinical evidence is limited and that you only use what has regulatory backing. This builds more trust than accepting the request so as not to lose the sale. Record the conversation and the consent, as in informed consent.

Does Harmy have anything to do with this?

Harmy does not recommend or simulate exosomes. The app's simulation works with areas and volumes in ml for volume and contour procedures, not with skin-quality therapies. A patient who seeks exosomes to "rejuvenate" will not see that represented in the projection, and it is important not to suggest they will. Use the app for what it does: supporting the conversation about volume and contour with an illustrative simulation.

Summary

Exosomes are a real field of research, but with a poorly standardized product, limited clinical evidence and a relevant regulatory risk. Check the registration, require documentation, inform the patient honestly and prefer to wait for evidence and approval rather than take on the risk of being the first to inject. To follow the science with a method, see how to keep up with the scientific literature.